Tech Company Financing Transactions
Wugen Funding Round
Wugen, based in St. Louis, secured $115 million from Fidelity Management & Research Company, Abingworth and Aisling Capital.
Transaction Overview
Company Name
Announced On
8/28/2025
Transaction Type
Venture Equity
Amount
$115,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to advance the ongoing pivotal T-RRex study of WU-CART-007 in relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4260 Forest Park Ave 100
St. Louis, MO 63108
USA
St. Louis, MO 63108
USA
Phone
Website
Email Address
Not Recorded
Overview
Wugen, Inc. is a pivotal-stage American-born biotechnology company advancing the next generation of off-the-shelf cell therapies. Our allogeneic therapies are derived from healthy donor cells and are engineered to deliver robust anti-tumor activity. With our proprietary CAR-T platform, Wugen is addressing critical unmet needs in hematologic malignancies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kumar Srinivasan
Browse more venture capital transactions:
Prev: 8/28/2025: Mid-Atlantic Biotherapeutics venture capital transaction
Next: 8/28/2025: TWINport360 venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs